Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency
about
Cardiovascular imaging: what have we learned from animal models?Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsGLP-1 and cardioprotection: from bench to bedsideGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes.PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat HeartGlucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitusCardiovascular biology of the incretin system.Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the ratCardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Potential cardiovascular effects of incretin-based therapies.Cardioprotective effects of incretin during ischaemia-reperfusion.A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1.The impact of current and novel anti-diabetic therapies on cardiovascular risk.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Extra-pancreatic effects of incretin-based therapies.Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.Albiglutide: a review of its use in patients with type 2 diabetes mellitus.Mechanisms for the cardiovascular effects of glucagon-like peptide-1.Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure.Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature
P2860
Q26779676-68BADA14-0D8A-41E5-B855-D2203ADF2A6AQ27021870-40EA8634-7348-4A38-B97C-681279333BDBQ27024984-A0C8701B-BC95-4DE5-8A9B-2BE25DAE03D8Q33603384-EF3F91F9-6444-4638-A0DF-8736D1DF3557Q34566411-9989A37E-99F9-45A8-8756-339E8DBD7A38Q34785887-F7F70342-A6A0-4FB7-AE63-F763D18F623DQ35670896-E299363F-D285-452C-98F5-689F1D872F72Q35926588-6EB945C2-8DE6-4C9C-9B4D-D91E69931E27Q36484283-C2DED7F8-5D37-4045-9F6E-199019B0AE37Q37367934-4DFF92F9-D687-4C86-BF57-940F670DA467Q37611715-DCF64F53-274B-4174-B622-1EE411B81EFFQ37990619-03FE5862-4028-494B-B782-D17CEC98C9A6Q38002006-4C90F169-9DE1-4617-90F6-953B6D97732EQ38035684-83C244CF-ABCD-4AB5-A379-422501A68FABQ38062033-6070C6A1-CEC8-452E-A36D-A8F28BE7B464Q38119146-94528811-6557-46F7-A7FB-2415C59EDC2CQ38174279-5F63938D-5CF0-4DE4-8396-707C1AB0CF73Q38194069-068A7CD5-16C4-4AC8-8CF6-C5BB914D1C46Q38218639-A58C71E4-BBD6-408D-912F-7C3468106E23Q38380559-904DE2A1-652F-4D35-89BE-DE340BBBF62FQ38589032-AE6809D4-6D31-4481-BE4B-A879CD4A9B45Q42050075-63303F0D-5A5B-4AEB-B392-01DFDD66E81EQ42736812-8A4D93FA-170E-44E4-BD1C-E3E53FFC16B3Q47275749-83E4CEA3-4714-4627-92B2-6F2537558F19Q57406244-E35FE580-C082-4DD2-BE38-9E5437F244A7
P2860
Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@ast
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@en
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@nl
type
label
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@ast
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@en
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@nl
prefLabel
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@ast
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@en
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@nl
P2093
P2860
P3181
P1433
P1476
Albiglutide, a long lasting gl ...... g cardiac metabolic efficiency
@en
P2093
Beat M Jucker
David R Citerone
Hasan Alsaid
John J Lepore
Karpagam Aravindhan
Mark R Harpel
Matthew Szapacs
Robert N Willette
Thimmaiah Chendrimada
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0023570
P407
P577
2011-01-01T00:00:00Z